Literature DB >> 13918321

A comparison of the effectiveness of standard dose 6-mercaptopurine, combination 6-mercaptopurine and DON, and high-loading 6-mercaptopurine therapies in treatment of the acute leukemias of childhood: results of a coperative study.

M P SULLIVAN, E C BEATTY, C B HYMAN, M L MURPHY, M I PIERCE, N C SEVERO.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS/therapy; LEUKEMIA/in infancy and childhood; MERCAPTOPURINE/therapy

Mesh：

Substances：

Year:  1962        PMID： 13918321

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  4 in total

1.  Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children.

Authors:  M P Sullivan; J A Nelson; S Feldman; B Van Nguyen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.

Authors:  Kathryn M Lemberg; Liang Zhao; Ying Wu; Vijayabhaskar Veeravalli; Jesse Alt; Joanna Marie H Aguilar; Ranjeet P Dash; Jenny Lam; Lukáš Tenora; Chabely Rodriguez; Michael T Nedelcovych; Cory Brayton; Pavel Majer; Jaishri O Blakeley; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2019-10-08       Impact factor: 6.261

3.  Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement.

Authors:  Jesse Alt; Sadakatali S Gori; Kathryn M Lemberg; Arindom Pal; Vijayabhaskar Veeravalli; Ying Wu; Joanna M H Aguilar; Ranjeet P Dash; Lukáš Tenora; Pavel Majer; Qi Sun; Barbara S Slusher; Rana Rais
Journal:  Curr Drug Metab       Date:  2021       Impact factor: 3.731

Review 4.  We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Authors:  Kathryn M Lemberg; James J Vornov; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.009
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.